133 related articles for article (PubMed ID: 10090791)
21. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB
Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830
[TBL] [Abstract][Full Text] [Related]
22. New orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
[TBL] [Abstract][Full Text] [Related]
23. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
Bioorg Med Chem Lett; 2000 Oct; 10(19):2235-8. PubMed ID: 11012037
[TBL] [Abstract][Full Text] [Related]
24. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
[TBL] [Abstract][Full Text] [Related]
25. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
26. Discovery of new orally active phosphodiesterase (PDE4) inhibitors.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1098-104. PubMed ID: 15340197
[TBL] [Abstract][Full Text] [Related]
27. Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.
Hirose R; Manabe H; Nonaka H; Yanagawa K; Akuta K; Sato S; Ohshima E; Ichimura M
Eur J Pharmacol; 2007 Nov; 573(1-3):93-9. PubMed ID: 17658510
[TBL] [Abstract][Full Text] [Related]
28. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration.
Kuss H; Hoefgen N; Johanssen S; Kronbach T; Rundfeldt C
J Pharmacol Exp Ther; 2003 Oct; 307(1):373-85. PubMed ID: 12944497
[TBL] [Abstract][Full Text] [Related]
29. Aryl sulfonamides as selective PDE4 inhibitors.
Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
[TBL] [Abstract][Full Text] [Related]
30. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity.
Aoki M; Kobayashi M; Ishikawa J; Saita Y; Terai Y; Takayama K; Miyata K; Yamada T
J Pharmacol Exp Ther; 2000 Oct; 295(1):255-60. PubMed ID: 10991987
[TBL] [Abstract][Full Text] [Related]
31. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
32. Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs.
Aoki M; Yamamoto S; Kobayashi M; Ohga K; Kanoh H; Miyata K; Honda K; Yamada T
J Pharmacol Exp Ther; 2001 Apr; 297(1):165-73. PubMed ID: 11259541
[TBL] [Abstract][Full Text] [Related]
33. Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Fattori R; Ferlenga P; Pradella L
Bioorg Med Chem Lett; 2002 Jan; 12(1):5-8. PubMed ID: 11738561
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors.
Ochiai H; Odagaki Y; Ohtani T; Ishida A; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Kobayashi K; Nakai H; Toda M
Bioorg Med Chem; 2004 Oct; 12(19):5063-78. PubMed ID: 15351390
[TBL] [Abstract][Full Text] [Related]
35. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
37. Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.
Guay D; Hamel P; Blouin M; Brideau C; Chan CC; Chauret N; Ducharme Y; Huang Z; Girard M; Jones TR; Laliberté F; Masson P; McAuliffe M; Piechuta H; Silva J; Young RN; Girard Y
Bioorg Med Chem Lett; 2002 Jun; 12(11):1457-61. PubMed ID: 12031319
[TBL] [Abstract][Full Text] [Related]
38. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.
Van der Mey M; Hatzelmann A; Van der Laan IJ; Sterk GJ; Thibaut U; Timmerman H
J Med Chem; 2001 Aug; 44(16):2511-22. PubMed ID: 11472205
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
